| Identification | Back Directory | [Name]
Ibrutinib Impurity 9 | [CAS]
2068022-09-1 | [Synonyms]
Ibrutinib Impurity 3-d5
N-(1-((S)-1-acryloylpiperidin-3-yl)-
Ibrutinib Impurity 3-d5 (PCI-45227-d5)
Ibrutinib Impurity 3-d5 (PCI-45227-d5)(Mixture of Diastereomers)
1-((R)-3-(4-Amino-3-(4-(phenoxy-d5)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2,3-dihydroxypropan-1-one
1-[(3R)-3-[4-amino-3-[4-(2,3,4,5,6-pentadeuteriophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-2,3-dihydroxypropan-1-one | [Molecular Formula]
C25H21D5N6O4 | [MOL File]
2068022-09-1.mol | [Molecular Weight]
479.543 |
| Hazard Information | Back Directory | [Uses]
Dihydrodiol-Ibrutinib-d5 is the deuterium labeled Dihydrodiol-Ibrutinib (HY-100659). Dihydrodiol-Ibrutinib is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib[1]. | [References]
[1] Sridhar Veeraraghavan,et al. Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. J Pharm Biomed Anal DOI:10.1016/j.jpba.2014.11.041 |
|
|